“…As stated above, compounds acting as agonists on dopamine D 2 /D 3 receptors, such as bromocriptine, piribedil, pramipexole, and roxindole (Post et al, 1978;Bouras and Bridges, 1982;Willner, 1983a;Borsini et al, 1988;Muscat et al, 1992;Grunder et al, 1993;Willner et al, 1994;Maj et al, 1996b;Corrigan et al, 2000), and compounds that enhance dopamine levels inhibiting selective dopamine reuptake like amineptine, nomifensine, and bupropion (Kinney, 1985;Dalery et al, 1997), have shown antidepressant-like activity in both preclinical models and clinical settings. Interestingly, it has been proposed that an increase in dopamine activity induced by chronic antidepressant treatments is one of the mechanisms of action underlying the efficacy of these compounds, since their effects are antagonized by low doses of D 2 /D 3 antagonists (Borsini et al, 1984;Borsini et al, 1985a, b;Pulvirenti and Samanin, 1986;Sampson et al, 1991;Serra et al, 1992;D'Aquila et al, 2000a). Moreover, antidepressant treatments are associated with increased dopaminergic function in the mesolimbic system and increased behavioral response to dopamine agonists (Spyraki and Fibiger, 1981;Maj et al, 1984a, b;Cervo and Samanin, 1987;De Montis et al, 1990;Ainsworth et al, 1998a;D'Aquila et al, 2000bD'Aquila et al, , 2003, which takes place after chronic treatment (2-3 weeks), a period of time that correlates with that necessary for the onset of antidepressant activity in the clinic.…”